Benzinga | May 12, 2021 06:56AM EDT

CTI BioPharma Completes Recruitment In Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib

https://clinicaltrials.gov/ct2/show/NCT04884191